Akums Drugs & Pharmaceuticals Ltd. has partnered with Triple Hair Group, a Canadian company specializing in the development of innovative treatments for androgenic alopecia, for the exclusive licensing of their patented topical formulation for the Indian market.

This advanced formulation combines three unique medicaments to combat alopecia, a common condition affecting millions in India and worldwide.

The newly licensed topical solution is designed to provide a comprehensive approach to hair care. It works to prevent hair fall, stimulate new hair growth, and enhance hair thickness and density, offering a one-stop solution for those battling hair thinning and baldness. This cutting-edge formula promises a convenient and effective option for users who prefer topical treatments, with the potential to improve compliance and outcomes for individuals struggling with hair loss.

Sanjeev Jain, Managing Director, Akums shared, “Akums' collaboration with Triple Hair marks a significant step towards expanding our dermatology portfolio and providing innovative and effective solutions for hair care in the Indian market. This partnership accentuates Akums’ commitment to delivering high-quality and clinically proven formulations to improve the lives of its consumers.”

Commenting on the partnership, Sandeep Jain, Managing Director, Akums, said, "We are thrilled to partner with Triple Hair, Canada, in bringing this unique formulation to the Indian market. This collaboration aligns with our vision of offering cutting-edge solutions that cater to the evolving needs of our customers. This patented formulation is set to revolutionize the way alopecia is treated in India, and we are confident that this product will help many people regain their confidence and self-esteem."

Jean-Philippe Gravel, CEO of Triple Hair, said, “We are proud to partner with Akums in what could be a very beneficial opportunity for both companies. One of the great advantages of this partnership is that Akums will be directly involved in the regulatory process, including an upcoming Phase III clinical trial in India. We expect to start the process in the coming weeks so that we can commercialize Therapy-07 in India as soon as possible.”